Trial reportKidney & blood pressure research2026
Overweight and Obesity Are Associated with Lower Renal Blood Flow in Autosomal Dominant Polycystic Kidney Disease.
Trial report in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Renal blood flow and progression to kidney failure in ADPKD.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Observational
- Texture Analysis of Multiparametric Kidney MRI-A Non-Invasive Approach to Chronic Kidney Disease State.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionWe have previously reported that overweight and obesity are independently associated with more rapid disease progression in adults with autosomal dominant polycystic kidney disease (ADPKD). In this study, we perform a cross-sectional analysis to evaluate whether overweight and obesity are also associated with renal blood flow (RBF) in this patient population.
methodsA total of 134 non-diabetic adults with ADPKD and estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 who participated in a randomized controlled trial of pravastatin therapy were categorized as normal weight, overweight, or obese, based on baseline adjusted body mass index (BMI), calculated after subtracting magnetic resonance imaging (MRI)-derived kidney and liver mass from body weight. RBF was measured by phase contrast MRI and adjusted for body surface area (BSA) prior to analysis. The association of baseline BMI with baseline RBF was assessed using multivariable linear regression models.
resultsParticipants were 40 ± 10 years (mean ± SD), 67% female, with a baseline RBF of 635 ± 214 mL/min/1.73 m2, and a baseline Chronic Kidney Disease Epidemiology (CKD-EPID) eGFR of 90 ± 21 mL/min/1.73 m2. BSA-adjusted RBF was lower in a stepwise manner with increasing BMI category. After adjustment for demographics, systolic blood pressure, blood glucose, high-density lipoprotein, blood pressure medication usage, eGFR, and height-adjusted total kidney volume, both overweight (β-estimate: -78.4; 95% CI: -155.3, -1.6) and obesity (β-estimate: -190.6; 95% CI: -307.4, -73.7) remained significantly associated with lower RBF as compared to normal weight participants. For every one unit increase in BMI, RBF was 10.4 mL/min/1.73 m2 lower (95% CI: -16.9, -3.9) in the fully adjusted model.
conclusionOverweight and obesity are cross-sectionally associated with lower RBF in patients with early-stage ADPKD; however, these findings reflect associations only and do not provide insight into causality. Further research and longitudinal studies are needed to establish the temporal and causal nature of these relationships and to evaluate whether reduced RBF may be a mechanism by which obesity is associated with faster progression in patients with ADPKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.